Tempy is a shared fever and medication tracking app for parents, featuring weight-based dosage calculators and cross-dosing safety alerts on iOS and Android.
The App DNA
What makes this app unique?
The app removes the cognitive friction of manual fever logging and medication timing, replacing fragmented notes with a synchronized, medically-aligned record for multiple caregivers.
For Parents and caregivers seeking a structured, shared, and medically-guided way to track child fevers and medication schedules.
What does it look like?
Key features
Real-time synchronization of fever and medication logs across multiple devices using a 6-digit invite code.
Calculates medication dosage based on child weight following FDA and AAP pediatric guidelines.
Enforces a 3-hour minimum interval between different medications to prevent accidental overdose.
How much does it cost?
Freemium model utilizing ad-supported inventory to monetize the free user base while gating advanced clinical tools.
Velocity
Active developmentUX improvementsShow more...
Tempy maintains an active development pace, shipping 2 releases in the observed window with an average of one update every 1-2 weeks. The latest release addresses synchronization consistency between notebooks, indicating a focus on core functionality and UX improvements. Development appears stable, with the publisher providing specific, albeit brief, context for recent changes. The app is currently in an active state, prioritizing functional reliability over frequent feature expansion.
Who built it?
Eodin
4 apps tracked · Health & Fitness
Arden: Read Aloud Story App
Cubist: 3x3 Cube Timer & Learn
Plori: Audio Tour GuideUser Sentiment
What do users think recently?
The recent review mood reads frustrated.
How are ratings & reviews evolving?
What users say, by theme
- Inability to correct medication timestamps after entry prevents accurate tracking for caregivers and patients
2 of 2 recent reviews analyzed · limited sample
Read the full review analysisUnlock 1 more frustration theme, each backed by review evidence.
Access the full report for freeCompetition
Competitive landscape for Tempy: Calm Fever Tracker
How's the Health & Fitness market?
Tempy maintains a 3.67-star rating across its early user base on iOS. The current lack of Android ratings suggests the platform is still in the initial acquisition phase, where feature parity and UX stability are the primary drivers of retention.
Read the market outlookThe rivals identified
Unlock the deeper market read.
Access the full report for freeThe Analyst's Read
Key takeaways for Tempy: Calm Fever Tracker
Where is it heading?
The fever-tracking market is consolidating around apps that provide high-accuracy, low-friction entry. Tempy's current trajectory is exposed by UX regressions that prevent it from becoming a reliable daily tool, so resolving these technical blockers is the only way to secure long-term retention.
- Persistent medication-editing and timeline-scaling complaints in the latest version erode trust, which directly increases churn risk for new parents.
- The active 10-day release cadence demonstrates a commitment to iteration, providing a window to resolve UX regressions before the user base plateaus.
The SWOT
- Cross-dosing protection mechanism enforces 3-hour safety intervals
- Localized fever-outbreak alerts offer utility for parents in high-risk regions
Next best moves
Enable medication timestamp editing because user reviews flag it as a primary tracking failure → improve data accuracy
+ 1 more prioritized moveThe counter-intuitive read
The focus on global outbreak alerts is a…
Read the full takeSince the last report: Tempy's strategic focus shifted toward localized outbreak alerts while the app's outlook declined to mixed due to persistent, unresolved medication-editing and timeline-scaling regressions.
Bottom line
Addressing the medication-editing and timeline-scaling regressions is necessary to stabilize the user base, as these core utility failures currently undermine the app's clinical value proposition.
Unlock 1 critical friction, 1 market threat, 1 more prioritized move and the analyst’s take.
Access the full report for freeSources
- [1] App Store, source
Report last updated